Catalyst Pharmaceuticals (CPRX) Operating Leases (2019 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Operating Leases came in at $2.2 million in Q1 2026, down 16.64% YoY from $2.7 million in Q1 2025, and down 4.89% on a QoQ basis from $2.4 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Operating Leases (2019 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 8 years of Operating Leases data on file, last reported at $2.2 million in Q1 2026.
- Quarterly Operating Leases fell 16.64% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 16.64% YoY) and the FY2025 annual result came in at $2.4 million, down 15.65% from the prior year.
- Operating Leases retreated to $2.2 million in Q1 2026, from $2.4 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $4.1 million in Q2 2022 to a low of $2.2 million in Q1 2026.
- A 5-year average of $3.2 million and a median of $3.2 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases changed 0.0% — and 2025, when it dropped 22.69%.
- Tracing CPRX's Operating Leases over 5 years: stood at $3.6 million in 2022, then retreated by 10.37% to $3.2 million in 2023, then slipped by 12.61% to $2.8 million in 2024, then dropped by 15.65% to $2.4 million in 2025, then slipped by 4.89% to $2.2 million in 2026.
- The last three Operating Leases figures came in at $2.2 million (Q1 2026), $2.4 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.24 Mn |
| Dec 31, 2025 | 2.35 Mn |
| Sep 30, 2025 | 2.46 Mn |
| Jun 30, 2025 | 2.57 Mn |
| Mar 31, 2025 | 2.68 Mn |
| Dec 31, 2024 | 2.79 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Mar 31, 2024 | 3.47 Mn |
| Dec 31, 2023 | 3.19 Mn |
| Sep 30, 2023 | 3.64 Mn |
| Jun 30, 2023 | 3.73 Mn |
| Mar 31, 2023 | 3.81 Mn |
| Dec 31, 2022 | 3.56 Mn |
| Sep 30, 2022 | 3.97 Mn |
| Jun 30, 2022 | 4.05 Mn |
| Mar 31, 2022 | 3.81 Mn |
| Dec 31, 2021 | 3.89 Mn |
| Sep 30, 2021 | 3.97 Mn |
| Jun 30, 2021 | 4.25 Mn |